Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Total Non-Current Liabilities (2021 - 2025)

Historic Total Non-Current Liabilities for Abeona Therapeutics (ABEO) over the last 11 years, with Q3 2025 value amounting to $37.3 million.

  • Abeona Therapeutics' Total Non-Current Liabilities fell 4940.79% to $37.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.3 million, marking a year-over-year decrease of 4940.79%. This contributed to the annual value of $32.9 million for FY2024, which is 8450.4% up from last year.
  • Latest data reveals that Abeona Therapeutics reported Total Non-Current Liabilities of $37.3 million as of Q3 2025, which was down 4940.79% from $52.5 million recorded in Q2 2025.
  • Abeona Therapeutics' 5-year Total Non-Current Liabilities high stood at $73.7 million for Q3 2024, and its period low was $16.9 million during Q3 2023.
  • Its 5-year average for Total Non-Current Liabilities is $30.5 million, with a median of $26.3 million in 2021.
  • As far as peak fluctuations go, Abeona Therapeutics' Total Non-Current Liabilities soared by 33551.13% in 2024, and later crashed by 4940.79% in 2025.
  • Over the past 5 years, Abeona Therapeutics' Total Non-Current Liabilities (Quarter) stood at $28.2 million in 2021, then tumbled by 36.92% to $17.8 million in 2022, then rose by 0.16% to $17.8 million in 2023, then soared by 84.5% to $32.9 million in 2024, then increased by 13.41% to $37.3 million in 2025.
  • Its last three reported values are $37.3 million in Q3 2025, $52.5 million for Q2 2025, and $33.2 million during Q1 2025.